Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019 to 2026
Asset Purchase Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2026
Benchmark Asset Acquisition Strategies Across the Global Biopharma Industry
The Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019–2026 report provides a comprehensive analysis of asset acquisition transactions across the global life sciences industry. Designed for business development, licensing, and corporate strategy professionals, the report delivers detailed insight into how companies structure asset purchase deals and negotiate the financial terms behind these transactions.
Fully revised and updated, the report analyzes asset purchase agreements announced since 2019, providing a detailed view of how pharmaceutical and biotechnology companies acquire business assets, product assets, royalty interests, and technology assets through strategic transactions.
Each deal record includes financial terms where available and links to detailed online deal records and contract documents filed with regulators when publicly disclosed. This combination of deal data, financial benchmarking, and contract access enables users to evaluate comparable transactions and structure more effective asset acquisition strategies.
Key Benefits
✔ Save Significant Research Time
Access a consolidated database of asset purchase deals rather than searching multiple press releases, databases, and regulatory filings.
✔ Benchmark Asset Purchase Deal Structures
Understand how pharmaceutical and biotechnology companies structure asset acquisition agreements across business units, products, technologies, and royalty streams.
✔ Analyze Financial Terms with Confidence
Review disclosed financial information—including headline deal values, upfront payments, milestones, and royalty arrangements—to benchmark transaction values and structures.
✔ Access Real Contract Documents
Where available, explore SEC-filed asset purchase agreements, providing deeper insight into the contractual provisions behind real-world deals.
✔ Identify the Most Active Asset Acquisition Dealmakers
Discover which companies are most active in asset acquisitions and analyze their strategic transaction activity.
✔ Track Industry Trends
Analyze asset purchase dealmaking trends since 2019 across companies, therapeutic areas, and technology types.
What’s Included in the Report
-
Analysis of asset purchase dealmaking trends since 2019
-
Overview of asset acquisition deal structures and transaction models
-
Review of the leading asset purchase deals by headline value
-
Profiles of the top 25 most active asset purchase dealmakers
-
Detailed analysis of deals organized by company, therapeutic area, technology type, and industry sector
-
A comprehensive deal directory covering asset purchase transactions announced since 2019
-
Links to online deal records and contract documents where available
Due Diligence Insights from Real Agreements
By reviewing actual asset purchase contracts, the report enables users to evaluate key transaction provisions such as:
-
Asset ownership and transfer rights
-
Financial payment structures and transaction values
-
Intellectual property rights and technology transfer provisions
-
Commercialization and development obligations
-
Royalty structures and ongoing financial participation
-
Contract duration and termination provisions
Access to real agreements provides insight into the detailed terms negotiated between companies—information rarely disclosed in press releases or traditional deal databases.
Why This Report Matters
Asset purchase transactions are an important strategic tool in the pharmaceutical and biotechnology industries, enabling companies to acquire technologies, products, and royalty streams to strengthen their pipelines and portfolios.
By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to evaluate acquisition opportunities, structure stronger asset purchase agreements, and negotiate more effectively.
Key Benefits
✔ Save Significant Research Time
Access a consolidated database of asset purchase deals rather than searching multiple press releases, databases, and regulatory filings.
✔ Benchmark Asset Purchase Deal Structures
Understand how pharmaceutical and biotechnology companies structure asset acquisition agreements across business units, products, technologies, and royalty streams.
✔ Analyze Financial Terms with Confidence
Review disclosed financial information—including headline deal values, upfront payments, milestones, and royalty arrangements—to benchmark transaction values and structures.
✔ Access Real Contract Documents
Where available, explore SEC-filed asset purchase agreements, providing deeper insight into the contractual provisions behind real-world deals.
✔ Identify the Most Active Asset Acquisition Dealmakers
Discover which companies are most active in asset acquisitions and analyze their strategic transaction activity.
✔ Track Industry Trends
Analyze asset purchase dealmaking trends since 2019 across companies, therapeutic areas, and technology types.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in asset purchase dealmaking
2.1. Introduction
2.2. Types of assets purchased
2.3. Trends in asset purchase deals since 2019
2.3.1. Asset purchase dealmaking by year
2.3.2. Asset purchase dealmaking by phase of development
2.3.3. Asset purchase dealmaking by industry sector
2.3.4. Asset purchase dealmaking by therapy area
2.3.5. Asset purchase dealmaking by technology type
2.3.6. Asset purchase dealmaking by most active company
2.4. Reasons for entering into asset purchase partnering deals
2.4.1. Business assets
2.4.2. Product assets
2.4.3. Royalty assets
2.4.4. Technology assets
2.5. The future of asset purchase deals
Chapter 3 – Overview of asset purchase deal structure
3.1. Introduction
3.2. Asset purchase agreement structure
Chapter 4 – Leading asset purchase deals
4.1. Introduction
4.2. Top asset purchase deals by value
Chapter 5 – Top 25 most active asset purchase dealmakers
5.1. Introduction
5.2. Top 25 most active asset purchase dealmakers
Chapter 6 – Asset purchase deals including contracts directory
6.1. Introduction
6.2. Asset purchase deals with contracts
Deal directory
Deal directory – Asset purchase dealmaking by companies A-Z
Deal directory – Asset purchase dealmaking by therapy area
Deal directory – Asset purchase dealmaking by technology type
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of assets purchased
Figure 2: Trends in asset purchase deal announcements
Figure 3: Asset purchase deals signed at each phase of development
Figure 4: Asset purchase deals by industry sector
Figure 5: Asset purchase deals by therapy area
Figure 6: Asset purchase deals by technology type
Figure 7: Top 25 most active asset purchase dealmakers
Figure 8: Top asset purchase deals by value
Figure 9: Most active asset purchase dealmakers
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in County Durham, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from primary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
